Williams Jones Wealth Management LLC. Decreases Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Williams Jones Wealth Management LLC. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 324,521 shares of the company's stock after selling 16,932 shares during the period. IDEXX Laboratories makes up approximately 1.6% of Williams Jones Wealth Management LLC.'s holdings, making the stock its 18th biggest holding. Williams Jones Wealth Management LLC. owned 0.40% of IDEXX Laboratories worth $134,170,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Hurley Capital LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth $29,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the fourth quarter worth about $30,000. Colonial Trust Co SC boosted its holdings in IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after acquiring an additional 39 shares in the last quarter. Kestra Investment Management LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $38,000. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after acquiring an additional 81 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $521.68 on Tuesday. The firm's fifty day moving average is $433.47 and its two-hundred day moving average is $432.18. The firm has a market cap of $41.95 billion, a price-to-earnings ratio of 48.89, a PEG ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $545.43. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.71 earnings per share. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on IDXX shares. Stifel Nicolaus lifted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday. Morgan Stanley lifted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Finally, StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.